@article{JGO3402,
author = {Aaron T. Wild and Avani S. Dholakia and Katherine Y. Fan and Rachit Kumar and Shalini Moningi and Lauren M. Rosati and Daniel A. Laheru and Lei Zheng and Ana De Jesus-Acosta and Susannah G. Ellsworth and Amy Hacker-Prietz and Khinh R. Voong and Phuoc T. Tran and Ralph H. Hruban and Timothy M. Pawlik and Christopher L. Wolfgang and Joseph M. Herman},
title = {Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas},
journal = {Journal of Gastrointestinal Oncology},
volume = {6},
number = {2},
year = {2014},
keywords = {},
abstract = {Background: Pancreatic adenosquamous carcinoma (PASC) accounts for only 1-4% of all exocrine pancreatic cancers and carries a particularly poor prognosis. This retrospective study was performed to determine whether inclusion of a platinum agent as part of adjuvant therapy is associated with improved survival in patients with resected PASC.
Methods: Records of all patients who underwent pancreatic resection at Johns Hopkins Hospital from 1986 to 2012 were reviewed to identify those with PASC. Multivariable Cox proportional hazards modeling was used to assess for significant associations between patient characteristics and survival.
Results: In total, 62 patients (1.1%) with resected PASC were identified among 5,627 cases. Median age was 68 [interquartile range (IQR), 57-77] and 44% were female. Multivariate analysis revealed that, among all patients (n=62), the following factors were independently predictive of poor survival: lack of adjuvant therapy [hazard ratio (HR) =3.6; 95% confidence interval (CI), 1.8-7.0; P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/3402}
}